Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a Diabetic Population

Catheterization and Cardiovascular Interventions, 04/09/2012

In a diabetic population undergoing percutaneous coronary intervention (PCI), the use of an everolimus–eluting stents (EES) compared to paclitaxel–eluting stents (PES) was associated with lower rates of stent thrombosis; but after adjustment the composite r target lesion revascularization (TLR)–major adverse cardiac events (MACE) at 1 year was similar between both stents.


  • From March 2004 to May 2010, 968 consecutive diabetic patients underwent percutaneous coronary intervention (PCI) and implantation of an EES (n=388) or PES (n=580) at this institution.
  • In–hospital, 1–month, 6–month, and 1–year clinical outcomes were analyzed and compared.
  • Correlates of major adverse cardiac events (MACE) were identified.


  • Baseline clinical characteristics were similar between stent types except for more family history of coronary artery disease in the PES group and more insulin–dependent diabetes and unstable angina at initial diagnosis in the EES group.
  • The PES group had higher number of lesions treated, longer stents used, and a higher proportion of intravascular ultrasound and glycoprotein IIb/IIIa inhibitor use.
  • The EES group had more type C and distal lesions.
  • There was higher target lesion revascularization (TLR)–MACE in the PES group (3.3% vs. 1.0%, p=0.03) as well as a higher rate of stent thrombosis (ST) (8 patients vs. 0 in the EES group, p=0.03).
  • ST continued to be higher in the PES group at 6 and 12 months and mortality was higher at 12 months in the PES group (9.4% vs. 5.2%, p=0.02).
  • After adjustment, no significant differences were found between stent types on Cox regression analysis for hazard ratios at 1–year follow–up of TLR–MACE.

Print Article Summary Cat 2 CME Report